Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» diffuse large B-cell lymphoma
diffuse large B-cell lymphoma
Forty Seven and AstraZenca Team up on NHL Triple-Combination Therapy
BioSpace
Fri, 05/10/19 - 05:58 pm
AstraZeneca
Forty Seven
clinical trials
diffuse large B-cell lymphoma
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Fierce Pharma
Fri, 02/1/19 - 12:00 am
Novartis
Kymriah
CAR-T
UK
diffuse large B-cell lymphoma
Gilead Sciences
NICE rejects Novartis’ CAR-T in adult lymphoma
Pharmaforum
Wed, 09/19/18 - 11:22 pm
NICE
UK
Novartis
CAR-T
Kymriah
NHS
diffuse large B-cell lymphoma
Ph II Trials of DPX-Survivac in Combination with Ketruda Yield Positive Results in Patients With Diffuse Large B-cell Lymphoma
CP Wire
Tue, 09/18/18 - 09:47 am
IMV Inc
diffuse large B-cell lymphoma
DPX-Survivac
Ph II Trials of DPX-Survivac in Combination with Ketruda Yield Positive Results in Patients With Diffuse Large B-cell Lymphoma
Tue, 09/18/18 - 08:45 am
IMV Inc
diffuse large B-cell lymphoma
DPX-Survivac
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
CP Wire
Wed, 07/18/18 - 10:54 am
Cellectar
CLR 131
diffuse large B-cell lymphoma
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
Wed, 07/18/18 - 09:58 am
Cellectar
CLR 131
diffuse large B-cell lymphoma
ASH17: Benefit of Gilead's CAR-T remains durable over longer term
BioPharma Dive
Sun, 12/10/17 - 11:27 pm
ASH17
Gilead Sciences
CAR-T
Yescarta
diffuse large B-cell lymphoma
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
Endpoints
Sun, 12/10/17 - 11:10 am
ASH17
Novartis
Kymriah
DLBCL
CAR-T
diffuse large B-cell lymphoma
Novartis seeks European approval for cell therapy Kymriah
Reuters
Mon, 11/6/17 - 09:25 am
Novartis
Europe
CAR-T
Kymriah
diffuse large B-cell lymphoma
acute lymphoblastic leukemia
Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on
Endpoints
Tue, 10/31/17 - 09:38 am
Novartis
FDA
CAR-T
Kymriah
diffuse large B-cell lymphoma
FDA says yes to rapid-acting Rituxan
BioPharma Dive
Fri, 06/23/17 - 11:23 am
FDA
Roche
Rituxan Hycela
refractory follicular lymphoma
CLL
diffuse large B-cell lymphoma
Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait
TheStreet.com
Fri, 04/7/17 - 09:45 am
Novartis
Kite Pharma
CTL019
diffuse large B-cell lymphoma
Karyopharm shakes off clinical hold for lead cancer med
BioPharma Dive
Fri, 03/31/17 - 11:00 am
Karyopharm
Selinexor
clinical trials
solid tumors
diffuse large B-cell lymphoma
Multiple Myeloma
Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals
Medical Marketing and Media
Wed, 11/16/16 - 09:59 am
Kite Pharma
CAR-T
KTE-C19
diffuse large B-cell lymphoma
Novartis promises a speedy CAR-T pitch, boasts about its slate of blockbusters-to-be
Endpoints
Tue, 10/25/16 - 10:10 am
Novartis
CAR-T
CTL-019
acute lymphoblastic leukemia
diffuse large B-cell lymphoma
Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next
TheStreet.com
Tue, 09/27/16 - 09:56 am
Kite Pharma
CAR-T
FDA
KTE-C19
diffuse large B-cell lymphoma
Celgene gives up on lucrative new use for linchpin drug Revlimid, clouding hopes for $1B-plus revenue boost
Fierce Pharma
Tue, 07/26/16 - 09:46 pm
Celgene
Revlimid
diffuse large B-cell lymphoma
Celgene drug fails to extend survival in lymphoma study
Yahoo/Reuters
Mon, 07/25/16 - 06:26 pm
Celgene
clinical trials
Revlimid
diffuse large B-cell lymphoma
Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma
Market Realist
Wed, 07/6/16 - 09:48 am
AbbVie
Imbruvica
diffuse large B-cell lymphoma
Pages
« first
‹ previous
1
2
3
next ›
last »